Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

BACKGROUND: Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage paye...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Am Heart Assoc
Main Authors: Kansal, Anuraag R., Cowie, Martin R., Kielhorn, Adrian, Krotneva, Stanimira, Tafazzoli, Ali, Zheng, Ying, Yurgin, Nicole
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4889192/
https://ncbi.nlm.nih.gov/pubmed/27153871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003221
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki